Clinical trial
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
NCT00450892 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00450892 |
|---|---|
| Title | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer |
| Official title | A Phase I-II Study of Lapatinib and Docetaxel as Neoadjuvant Treatment for HER-2 Positive Locally Advanced/Inflammatory or Large Operable Breast Cancer |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel+lapatinib, docetaxel + trastuzumab, docetaxel + trastuzumab + lapatinib |
| Enrollment | 129 |
| Start date | Feb 1, 2007 |
| Primary completion | Jul 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Mar 22, 2007 |
| Last update posted | Jul 7, 2016 |
| Countries | Belgium, France, Slovenia, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: